Tural, D., Molinas Mandel, N., Dervisoglu, S., Oner Dincbas, F., Koca, S., Colpan Oksuz, D., Kantarci, F., Turna, H., Selcukbiricik, F. and Hiz, M. (2012) Extraskeletal Ewing’s Sarcoma Family of Tumors in Adults: Prognostic Factors and Clinical Outcome. Japanese Journal of Clinical Oncology, 42, 420-426.
https://doi.org/10.1093/jjco/hys027

has been cited by the following article:

• TITLE: Prognosis and Outcome of Adult Patients with Ewing Sarcoma (Local Experience)

  AUTHORS: Mohamed Ashour, Salem Al Shammari, Hanan Shafik, Ahmed Mohialdien

  KEYWORDS: Adult, Ewing, Sarcoma, Treatment

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.8, August 8, 2017

  ABSTRACT: Objective: Aim of this work is to assess clinical features, outcome and prognosis of adult patients diagnosed with Ewing Sarcoma (ES). Patients, Methods and Results: The records of 53 adult patients treated with Euro-Ewing protocol at Kuwait cancer control center (KCCC) over a period of 5 years were reviewed. Mean age was 26.9 ± 1.25 years. Thirty percent of patients presented with metastatic disease, and 65% of tumors were centrally located and 50% were ≥ 8 cm. All patients received initially VIDE protocol. 13.5% achieved complete remission (CR), and 57.7% achieved partial response (PR). Approximately 1/3 of patients underwent surgery which was adequate in 76% of them, and all patients received local radiotherapy. Post local treatment 56% of patients received VAC and 44% received VAI protocol. Mean treatment duration was 11 months ± 0.54. Median follow-up duration was 38.39 (33.49 - 43.28) months At the end of follow up 20% of patients relapsed locally and 36% distally. Median PFS was 46.9 months (95% CI 41.42 - 52.39), Median OS was 55.43 ms (95% CI 30.71 - 75.74); survivals at 3 and 5 years were 88%, 46% respectively. Conclusion: In this series metastases at presentation and wide surgical margins were the most important prognostic factors. Multimodality therapy is necessary for this rare disease.